Outpatient diagnosis and drug therapy of endometriosis: A review

А. Е. Солопова, Patimat M. Alieva, M R Dumanovskaya, Guzal I. Tabeeva, Iuliia A. Ivannikova, A. A. Smetnik, С. В. Павлович
In: Gynecology · 2024 · vol. 26(2) , pp. 135–140 · doi:10.26442/20795696.2024.2.202733 · W4399480579
review OA: gold CC0 ⤵ 1 in-corpus citation
🔓 Open OA copy View on OpenAlex View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This review covers outpatient diagnostic methods, including non-invasive imaging, and long-term pharmacotherapy options for endometriosis to improve quality of life and reproductive outcomes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-08 ⓘ

This 2024 review addresses outpatient diagnosis and drug therapy for endometriosis, focusing on how clinicians combine symptom assessment and risk factor review with noninvasive imaging (transvaginal/transrectal ultrasound and, when needed, MRI) to shorten time to diagnosis. It summarizes evidence that transvaginal/transrectal ultrasound can detect ovarian endometriomas and many larger extraovarian lesions, while MRI provides high diagnostic accuracy for lesion location and extent, including for deep infiltrating disease, though accuracy depends on image quality, preparation, and interpreter experience; the review notes that laparoscopy with histologic confirmation remains the “gold standard,” yet negative pathology does not always exclude disease. For treatment, it describes long-term pharmacotherapy goals aimed at controlling disease development and improving quality of life, reporting that timely drug initiation can improve quality of life and in some cases be associated with lesion regression and better reproductive prognosis, while emphasizing the need for long-term therapy and monitoring of the disease course. This paper is centrally about endometriosis — it reviews outpatient diagnostic pathways using noninvasive imaging and summarizes long-term pharmacotherapy approaches for endometriosis.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

Endometriosis affects about 10% of women of reproductive age and can negatively impact their quality of life (QoL). Due to the heterogeneity of symptoms or even their absence, early diagnosis is difficult. Therefore, it is necessary to comprehensively assess the patient's complaints, including a thorough review of medical history, the results of imaging studies, and risk factors for endometriosis. Early diagnosis enables preemptive treatment and avoids surgical intervention. The article presents data on managing patients with endometriosis in outpatient settings, describing methods for non-invasive imaging diagnosis of endometriosis. Current options of pharmacotherapy aimed at controlling the development of the disease and improving the QoL of patients in the long term are addressed. Timely initiated drug treatment improves the QoL of patients, in some cases, leads to a regression of the lesions, and improves the prognosis for the reproductive function. A shift in focus to clinical diagnosis, combined with non-invasive imaging, shortens the time between the first consultation and the final diagnosis. According to the current view of Russian and international professional societies, therapy should be long-term; therefore, selecting treatment with predictable responses and monitoring the course of the disease is necessary.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (61)

Cited by (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK